58.21
price up icon0.83%   0.48
after-market アフターアワーズ: 58.21
loading
前日終値:
$57.73
開ける:
$58.01
24時間の取引高:
1.17M
Relative Volume:
0.64
時価総額:
$11.46B
収益:
$4.08B
当期純損益:
$32.48M
株価収益率:
415.79
EPS:
0.14
ネットキャッシュフロー:
$16.80M
1週間 パフォーマンス:
+5.51%
1か月 パフォーマンス:
-6.13%
6か月 パフォーマンス:
-12.37%
1年 パフォーマンス:
+10.41%
1日の値動き範囲:
Value
$57.08
$58.69
1週間の範囲:
Value
$55.11
$59.95
52週間の値動き範囲:
Value
$50.35
$83.95

Incyte Corp Stock (INCY) Company Profile

Name
名前
Incyte Corp
Name
セクター
Healthcare (1151)
Name
電話
(302) 498-6700
Name
住所
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
職員
2,617
Name
Twitter
@Incyte
Name
次回の収益日
2025-02-10
Name
最新のSEC提出書
Name
INCY's Discussions on Twitter

INCY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
INCY
Incyte Corp
58.21 11.46B 4.08B 32.48M 16.80M 0.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

Incyte Corp Stock (INCY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-18 ダウングレード Guggenheim Buy → Neutral
2025-03-18 ダウングレード William Blair Outperform → Mkt Perform
2024-12-17 開始されました UBS Neutral
2024-10-29 アップグレード BofA Securities Neutral → Buy
2024-10-01 開始されました Wolfe Research Outperform
2024-09-18 ダウングレード Truist Buy → Hold
2024-07-02 ダウングレード BMO Capital Markets Market Perform → Underperform
2024-05-23 開始されました Deutsche Bank Hold
2024-04-23 開始されました Cantor Fitzgerald Neutral
2024-02-23 開始されました Jefferies Buy
2024-02-14 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 アップグレード Leerink Partners Market Perform → Outperform
2023-12-04 アップグレード Guggenheim Neutral → Buy
2023-11-21 ダウングレード Goldman Buy → Neutral
2023-07-25 開始されました Citigroup Buy
2023-05-04 ダウングレード BofA Securities Buy → Neutral
2023-04-10 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-03-24 アップグレード SVB Securities Underperform → Market Perform
2023-01-31 開始されました Piper Sandler Overweight
2022-08-03 ダウングレード Evercore ISI Outperform → In-line
2022-08-03 ダウングレード Guggenheim Buy → Neutral
2022-07-28 開始されました Wells Fargo Equal Weight
2022-02-09 ダウングレード SVB Leerink Mkt Perform → Underperform
2022-01-18 アップグレード RBC Capital Mkts Sector Perform → Outperform
2021-11-19 開始されました BMO Capital Markets Market Perform
2021-07-20 アップグレード The Benchmark Company Hold → Buy
2021-02-10 ダウングレード SVB Leerink Mkt Perform → Underperform
2021-01-07 開始されました Truist Buy
2021-01-04 アップグレード Guggenheim Neutral → Buy
2020-06-16 開始されました The Benchmark Company Hold
2020-05-06 ダウングレード JP Morgan Overweight → Neutral
2020-04-29 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-04-01 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-24 再開されました William Blair Outperform
2020-03-13 アップグレード BofA/Merrill Neutral → Buy
2020-02-04 再開されました BofA/Merrill Neutral
2020-01-03 繰り返されました BMO Capital Markets Market Perform
2020-01-03 ダウングレード Mizuho Buy → Neutral
2020-01-02 ダウングレード Guggenheim Buy → Neutral
2019-10-03 開始されました Mizuho Buy
2019-09-12 開始されました BMO Capital Markets Market Perform
2019-09-05 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 再開されました Morgan Stanley Equal-Weight
2019-09-05 アップグレード Oppenheimer Perform → Outperform
2019-05-21 開始されました Credit Suisse Neutral
2019-05-03 ダウングレード Barclays Overweight → Equal Weight
2019-04-11 開始されました Stifel Hold
2019-04-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2019-01-24 アップグレード William Blair Mkt Perform → Outperform
すべてを表示

Incyte Corp (INCY) 最新ニュース

pulisher
04:36 AM

Incyte Grants Restricted Stock Units to New Employees - MSN

04:36 AM
pulisher
04:26 AM

Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.

04:26 AM
pulisher
Apr 17, 2025

Incyte Can Get Novartis' Privileged Info On Drug Royalty Deal - Law360

Apr 17, 2025
pulisher
Apr 16, 2025

Incyte Earnings Preview: What to Expect - inkl

Apr 16, 2025
pulisher
Apr 16, 2025

Incyte Earnings Preview: What To Expect - Barchart.com

Apr 16, 2025
pulisher
Apr 15, 2025

Incyte to Announce Q1 2025 Financial Results on April 29 - MSN

Apr 15, 2025
pulisher
Apr 14, 2025

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Apr 14, 2025
pulisher
Apr 13, 2025

Incyte (INCY) Revenue Surges, But Stock Drops 20% - GuruFocus

Apr 13, 2025
pulisher
Apr 11, 2025

Global Janus Kinase Inhibitors Market Surges at 8.4% CAGR - openPR.com

Apr 11, 2025
pulisher
Apr 11, 2025

Incyte to Report First Quarter Financial Results | INCY Stock Ne - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Incyte to Report First Quarter Financial Results - Business Wire

Apr 10, 2025
pulisher
Apr 09, 2025

Judges Skeptical of Incyte's Patent Block on Sun's Alopecia Drug - Bloomberg Law News

Apr 09, 2025
pulisher
Apr 08, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 7, 2025 - BioSpace

Apr 08, 2025
pulisher
Apr 07, 2025

Incyte Can't Get Pretrial Win In Novartis Royalty Fight - Law360

Apr 07, 2025
pulisher
Apr 07, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY) - Yahoo Finance

Apr 07, 2025
pulisher
Apr 03, 2025

Incyte Co. (NASDAQ:INCY) Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat

Apr 03, 2025
pulisher
Apr 02, 2025

Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com

Apr 02, 2025
pulisher
Apr 02, 2025

Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com

Apr 02, 2025
pulisher
Apr 02, 2025

1,764,725 Shares in Incyte Co. (NASDAQ:INCY) Acquired by Norges Bank - MarketBeat

Apr 02, 2025
pulisher
Apr 01, 2025

Incyte Stock: Is INCY Outperforming the Health Care Sector? - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Incyte Stock: Is INCY Outperforming The Health Care Sector? - Barchart.com

Apr 01, 2025
pulisher
Apr 01, 2025

3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Women in healthcare and life sciences - The Business Journals

Mar 31, 2025
pulisher
Mar 31, 2025

Incyte’s SWOT analysis: stock faces patent cliff challenge amid pipeline promise - Investing.com

Mar 31, 2025
pulisher
Mar 30, 2025

Meiji Yasuda Asset Management Co Ltd. Purchases 32,830 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat

Mar 30, 2025
pulisher
Mar 30, 2025

Incyte : U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir - MarketScreener

Mar 30, 2025
pulisher
Mar 27, 2025

Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment - MSN

Mar 27, 2025
pulisher
Mar 26, 2025

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Mar 26, 2025
pulisher
Mar 24, 2025

Incyte Had a Bad Week. Investors Are Used to It. - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Incyte’s Hold Rating: Balancing Pipeline Challenges and Established Product Valuation - TipRanks

Mar 24, 2025
pulisher
Mar 23, 2025

Compass Ion Advisors LLC Has $960,000 Position in Incyte Co. (NASDAQ:INCY) - MarketBeat

Mar 23, 2025
pulisher
Mar 22, 2025

Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts - TipRanks

Mar 22, 2025
pulisher
Mar 21, 2025

Why Incyte Stock Was Tanking This Week - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Incyte (INCY) Stock Declines Due to Clinical Trial Results - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance

Mar 21, 2025
pulisher
Mar 19, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Stock market unimpressed by results for Incyte acne drug as share price drops 11% - delawarebusinessnow.com

Mar 19, 2025
pulisher
Mar 19, 2025

Incyte price target lowered to $72 from $74 at Truist - Yahoo Finance

Mar 19, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BMV:INCY) - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BIT:1INCY) - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib (NASDAQ:INCY) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Marginal Zone Lymphoma Pipeline 2025: MOA and ROA Insights, - openPR

Mar 18, 2025
pulisher
Mar 18, 2025

INCY Stock Down on Disappointing Skin Disease Study Data - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte stock price target cut to $72 at Truist Securities - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte’s JAK1 blocker meets goals in Phase III trials - The Pharma Letter

Mar 18, 2025
pulisher
Mar 18, 2025

Jefferies cuts Incyte stock price target to $75, keeps Buy rating - Investing.com

Mar 18, 2025

Incyte Corp (INCY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
大文字化:     |  ボリューム (24 時間):